Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Corcept Therapeutics Incorporated (CORT) vs Halozyme Therapeutics, Inc. (HALO)

Corcept Therapeutics Incorporated and Halozyme Therapeutics, Inc. are both Biotechnology companies. Corcept Therapeutics Incorporated and Halozyme Therapeutics, Inc. are of similar size ($13.1B and $12.9B). Halozyme Therapeutics, Inc. trades at the lower P/E: 32.4× against 223×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against 16.0%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 6.53%) and the higher return on invested capital (18.1% vs 1.01%). Across the 22 metrics below, Halozyme Therapeutics, Inc. leads on 17 and Corcept Therapeutics Incorporated on 5.

Valuation

Metric CORT HALO Biotechnology median
P/E 223.27 32.36 7.88
P/S 14.73 8.03 11.47
P/B 17.33 93.06 2.52
Price to free cash flow 114.42 16.57 21.16
EV/EBITDA 3,205.62 21.24 0.74
EV/Sales 14.36 9.18 10.73
Earnings yield 0.45% 3.09% (28.84%)
Free cash flow yield 0.87% 6.04% (23.03%)

Profitability

Metric CORT HALO Biotechnology median
Gross margin 98.30% 82.42% 65.16%
Operating margin 0.77% 35.90% 0.00%
Net margin 6.53% 24.86% 0.00%
Free cash flow margin 12.87% 48.46% 0.00%
Return on equity 8.08% 173.67% (57.72%)
Return on assets 6.41% 17.86% (49.22%)
Return on invested capital 1.01% 18.13% 0.00%

Growth

Metric CORT HALO Biotechnology median
Revenue growth (TTM) 16.02% 41.15% 5.64%
EPS growth (last fiscal year) (33.33%) (25.36%) —
Revenue growth, 5-year CAGR 16.56% 39.16% 8.40%
Net income growth, 5-year CAGR (1.52%) 19.68% 0.00%

Health

Metric CORT HALO Biotechnology median
Debt to equity 0.00 14.95 0.00
Current ratio 2.86 2.71 4.73
Net debt to EBITDA (8.83) 3.56 0.96

Dividend

Metric CORT HALO Biotechnology median
Dividend yield 0.31% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CORT HALO Biotechnology median
Market cap 12.87b 13.08b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack